The targeted delivery of drug-loaded nanovesicles was examined on the TNF-alpha-treated human umbilical vein endothelial cells (HUVECs) or ICAM-1 expressing HT1080 cells in vitro and mouse CT26 tumour or human A549 tumour-bearing mice in vivo. Here, ICAM1 is linked to neoplasm.